222 related articles for article (PubMed ID: 9340560)
1. [AIDS; new developments. II. Treatment of HIV infection].
Borleffs JC; Esseveld F; Hoepelman IM; Boucher CA
Ned Tijdschr Geneeskd; 1997 May; 141(21):1036-43. PubMed ID: 9340560
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
3. New antiretrovirals and new combinations.
Havlir DV; Lange JM
AIDS; 1998; 12 Suppl A():S165-74. PubMed ID: 9632999
[TBL] [Abstract][Full Text] [Related]
4. Drugs for HIV infection.
Med Lett Drugs Ther; 1997 Dec; 39(1015):111-6. PubMed ID: 9402928
[No Abstract] [Full Text] [Related]
5. HIV treatment options.
Smith D
AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
8. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
9. Combination antiretroviral therapy for HIV infection.
Maenza J; Flexner C
Am Fam Physician; 1998 Jun; 57(11):2789-98. PubMed ID: 9636341
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of antiretroviral drugs.
Hoetelmans RM
Antivir Ther; 1999; 4 Suppl 3():29-41. PubMed ID: 16021869
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq E
Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
[TBL] [Abstract][Full Text] [Related]
12. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
13. Protease inhibitors and prevention of cross resistance.
Levin J
AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
[TBL] [Abstract][Full Text] [Related]
14. [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Aguirrebengoa K; Mallolas J; Uriz J; Torres Tortosa M
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():3-9. PubMed ID: 9053024
[No Abstract] [Full Text] [Related]
15. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
16. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
17. [HIV-therapy: as early and as intensive as possible].
Dtsch Med Wochenschr; 1997 Oct; 122(41):A27. PubMed ID: 9378051
[No Abstract] [Full Text] [Related]
18. Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.
Svedhem V; Lindkvist A; Lidman K; Sönnerborg A
J Med Virol; 2002 Dec; 68(4):473-8. PubMed ID: 12376953
[TBL] [Abstract][Full Text] [Related]
19. Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
Anderson RD
Antivir Ther; 1998; 3 Suppl 4():63-4. PubMed ID: 10723514
[TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
